高敏C反应蛋白/清蛋白比值及血浆和肽素对冠心病合并慢性心力衰竭患者主要不良心血管事件的预测价值

Abstract
Figure/Table
References (20)
Related Citation (0)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the predictive value of high sensitivity C-reactive protein and albumin ratio and plasma copeptin (CPP) on major adverse cardiovascular events (MACE) in patients with coronary heart disease and chronic heart failure. Methods Eighty-six hospitalized patients with coronary heart disease and chronic heart failure in People′s Hospital of Huaiyin Ji′nan from March 2018 to June 2019 were selected. According to the occurrence of MACE within 6 months, the patients were divided into the MACE group (36 cases) and the non-MACE group (50 cases). The data of all patients were collected, the serum brain natriuretic peptide (BNP), CPP levels, high-sensitivity C-reactive protein/albumin ratio and left ventricular ejection fraction (LVEF) were detected, and receiver operating characteristic (ROC) curve was used to evaluate the predictive value of high-sensitivity C-reactive protein/albumin ratio and CPP for MACE in patients with coronary heart disease and chronic heart failure. Results The high-sensitivity C-reactive protein/albumin ratio, plasma BNP and CPP levels of the MACE group were higher than those of the non-MACE group, and the LVEF was lower than that of the non-MACE group, the differences were statistically significant(P<0.05). The area under the curve (AUC) of MACE in patients with coronary heart disease and chronic heart failure predicted by the high-sensitivity C-reactive protein/albumin ratio was 0.826, P=0.000, 95%CI (0.735-0.917), which had certain diagnostic significance. The AUC of MACE in patients with coronary heart disease and chronic heart failure predicted by the plasma CPP was 0.714, P=0.000, 95%CI (0.604-0.824), which had certain diagnostic significance. The AUC was 0.865 in the occurrence of MACE in patients with coronary heart disease and chronic heart failure predicted by combination of high-sensitivity C-reactive protein/albumin ratio and plasma CPP, which was better than the above two independent indicators. Conclusion The high-sensitivity C-reactive protein/albumin ratio and CPP can be used as biomarkers for early prediction of MACE in patients with coronary heart disease and chronic heart failure.

Key words： Coronary heart disease complicated with chronic heart failure Major adverse cardiovascular events High sensitivity C-reactive protein/albumin Copeptin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Xiao-zhi WANG Le

Cite this article:

DU Xiao-zhi WANG Le. Predictive value of high sensitivity C-reactive protein/albumin ratio and plasma copeptin on major adverse cardiovascular events in patients with coronary heart disease and chronic heart failure[J]. 中国当代医药, 2020, 27(27): 16-19.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I27/16

[1]	Patel N，Gupta A，Doshi R，et al.In-hospital management andoutcomes after ST-segment-elevation myocardial infarction in medicaid beneficiaries compared with privately insured individuals[J].Circ Cardiovasc Qual Outcomes，2019，12（1）：e004971.
[2]	杨英，杨简，刘晓雯，等.急性ST 段抬高型心肌梗死患者急诊PCI 术后短期不良心血管事件发生情况及其影响因素[J].山东医药，2018，58（40）：10-14.
[3]	吴雨径，刘惠亮，李屹，等.血清NT-proBNP 与hs-CRP 在预测急性ST 段抬高性心肌梗死主要心脏不良事件的价值[J].现代生物医学进展，2016，16（17）：3317-3321.
[4]	Zhong Y，Wang R，Yan L，et al.Copeptin in heart failure：Review and meta-analysis[J].Clin Chim Acta，2017，475：36-43.
[5]	Yoshikawa Y，Shiomi H，Kuwahara K，et al.Utility of copeptin for predicting long-term clinical outcomes in patients with heart failure[J].J Cardiol，2019，73（5）：379-385.
[6]	沈迎，张奇，沈卫峰.美国和欧洲稳定性冠心病诊治指南解读[J].中华心血管病杂志，2014，42（1）：70-72.
[7]	Guerin M，Silvain J，Gall J，et al.Association of serum cholesterolefflux capacity with mortality in patients with STsegment elevationmyocardial infarction[J].J Am Coll Cardiol，2018，72（25）：3259-3269.
[8]	钱俊峰，姜红，葛均波.我国慢性心力衰竭流行病学和治疗现状[J].中国临床医学，2009，16（5）：700-703.
[9]	Shimoda T，Obsase Y，Kishikawa R，et al.Serum high-sensitivity C-reactive protein can be an airway inflammation predictor in bron-chial asthma[J].Allergy Asthma Proc，2015，36（2）：23-28.
[10]	Shaw JG，Vaughan A，Dent AG，et al.Biomarkers of progression of chronic obstructive pulmonary disease （COPD）[J].Thorac Dis，2014，6（11）：1532-1547.
[11]	Kimak E，Dzida G，Duma D，et al.Association between concentration of melatonin，and lipoproteins，LPO，hsCRP，NTproBNP in chronic heart failure patients[J].Cur Iss Pharm Med Sci，2014，27（3）：159-164.
[12]	叶宗伟，刘芬，赵倩，等.高敏C-反应蛋白与白蛋白比值对急性STEMI 患者预后的预测价值[J].临床心血管病杂志，2018，34（8）：760-764.
[13]	Neuhold S，Huelsmann M，Strunk G，et al.Comparison of copeptin，B-type natriuretic peptide，and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure：prediction of death at different stages of the disease[J].Am Coll Cardiol，2008，52（4）：266-272.
[14]	Tentzeris I，Jarai R，Farhan S，et al.Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure[J].Eur J Heart Fail，2011，13（7）：726-733.
[15]	Galla OJ，Ylitalo A，Kiviniemi A，et al.Peptide hormones and risk for future cardiovascular events among prediabetics：a 20-year follow-up in the OPERA study[J].Ann Med，2020，52（3-4）：85-93.
[16]	于红玖，杨明晖，吕田.慢性心力衰竭患者和肽素、尿酸水平变化及其临床意义[J].大连医科大学学报，2012，34（3）：244-247.
[17]	Alehagen U，Dahlstrm U，Rehfeld JF，Goetze JP.Association of Copeptin and N-Terminal proBNP Concentrations With Risk of Cardiovascular Death in Older Patients With Symptoms of Heart Failure[J].JAMA，2011，305（20）：2088-2095.
[18]	Yu HJ，Yang MH，Lv T.GW24-e1272 The clinical significance and the expression of copeptin and hemoglobin in patients with chronic heart failure[J].Heart，2013，99（Suppl 3）：A223.
[19]	Iwashita N，Nara N，Sato R，et al.Differential Regulation of Plasma Copeptin Levels in Patients with Heart Failure：A Single-Center Prospective Study[J].Tohoku J Exp Med，2016，239（3）：213-221.
[20]	邹莉玲，沈其君，陈启光，等.指标联合的ROC 曲线分析[J].中国卫生统计，2003，（5）：24-25.